Table 3.
Adverse events and complications stratified by TANDEM size and doxorubicin-loading concentration.
| Total n (%) | TANDEM size | Doxorubicin loading | |||||
|---|---|---|---|---|---|---|---|
| 75 μm n (%) | 100 μm n (%) | P-valuea | Half-loaded n (%) | Full-loaded n (%) | P-valuea | ||
| Procedure-related complication | 0.015 | 0.199 | |||||
| No | 76 (87.4%) | 19 (73.1%) | 57 (93.4%) | 15 (100.0%) | 61 (84.7%) | ||
| Yes | 11 (12.6%) | 7 (26.9%) | 4 (6.6%) | 0 (0.0%) | 11 (15.3%) | ||
| Post-embolization syndrome | 0.016 | 0.583 | |||||
| 0 | 51 (58.6%) | 10 (38.5%) | 41 (67.2%) | 12 (80.0%) | 39 (54.2%) | ||
| 1 | 21 (24.1%) | 8 (30.8%) | 13 (21.3%) | 2 (13.3%) | 19 (26.4%) | ||
| 2 | 10 (11.5%) | 7 (26.9%) | 3 (4.9%) | 1 (6.7%) | 9 (12.5%) | ||
| 3 | 4 (4.6%) | 1 (3.9%) | 3 (4.9%) | 0 (0.0%) | 4 (5.6%) | ||
| 4 | 1 (1.2%) | 0 (0.0%) | 1 (1.6%) | 0 (0.0%) | 1 (3.0%) | ||
| SIR Classification System for complications | 0.004 | 0.542 | |||||
| No | 51 (58.6%) | 10 (38.5%) | 41 (67.2%) | 12 (80.0%) | 39 (54.2%) | ||
| A | 21 (24.1%) | 8 (30.8%) | 13 (21.3%) | 2 (13.3%) | 19 (26.4%) | ||
| B | 11 (12.6%) | 8 (30.8%) | 3 (4.9%) | 1 (6.7%) | 10 (13.9%) | ||
| C | 3 (3.5%) | 0 (0.0%) | 3 (4.9%) | 0 (0.0%) | 3 (4.2%) | ||
| D | 1 (1.2%) | 0 (0.0%) | 1 (1.6%) | 0 (0.0%) | 1 (1.4%) | ||
| Adverse events | |||||||
| Abdominal pain | 23 (26.4%) | 11 (42.3%) | 12 (19.7%) | 0.036 | 3 (20.0%) | 20 (27.8%) | 0.750 |
| Fever | 17 (19.5%) | 5 (19.2%) | 12 (19.7%) | 1.000 | 0 (0.0%) | 17 (23.6%) | 0.036 |
| Acute gastritis | 1 (1.2%) | 1 (3.9%) | 0 (0.0%) | 0.299 | 0 (0.0%) | 1 (1.4%) | 1.000 |
| Reflux esophagitis | 1 (1.2%) | 1 (3.9%) | 0 (0.0%) | 0.299 | 0 (0.0%) | 1 (1.4%) | 1.000 |
| Nausea | 3 (3.5%) | 1 (3.9%) | 2 (3.3%) | 1.000 | 0 (0.0%) | 3 (4.2%) | 1.000 |
| Liver abscess | 1 (1.2%) | 0 (0.0%) | 1 (1.6%) | 1.000 | 0 (0.0%) | 1 (1.4%) | 1.000 |